The Cancer Test That Does Not Require a Tumour to Be Found Before It Looks
Liquid biopsy, the clinical testing approach that detects cancer-derived genetic material circulating in the bloodstream rather than requiring tissue extracted from a known tumour through invasive surgical or needle biopsy procedures, represents the most commercially significant diagnostic innovation in oncology since the introduction of PSA testing for prostate cancer in the 1980s, and the one whose commercial implications extend well beyond the oncology department into the primary care, health screening, and preventive medicine markets whose patient populations and revenue structures differ fundamentally from the specialist cancer centre environment where liquid biopsy entered clinical practice. The original clinical application of liquid biopsy was the monitoring of known cancer patients whose treatment response and residual disease detection required the longitudinal molecular tracking that repeated tissue biopsies cannot practically provide, and this companion diagnostics and treatment monitoring application created the early commercial revenue for Guardant Health, Foundation Medicine, and Tempus whose circulating tumour DNA assays detected the actionable mutations whose presence or absence guided the oncologist's treatment selection decisions. The application that is now reshaping the commercial landscape of liquid biopsy is multi-cancer early detection, in which a single blood draw is analysed for the DNA methylation patterns, protein biomarkers, or cell-free DNA fragments that indicate the presence of cancer at a stage earlier than symptoms appear and before the tumour has grown to the size detectable by conventional imaging, creating the population screening application whose addressable market is measured not in the tens of thousands of known cancer patients who need treatment monitoring but in the hundreds of millions of asymptomatic adults in the fifty-plus age bracket for whom annual or biennial multi-cancer screening creates the preventive medicine value proposition that primary care physicians, health insurers, and health system planners are beginning to assess against the evidence base accumulating from the large screening trials whose results are determining the regulatory pathway for multi-cancer early detection products.
The liquid biopsy market, valued at approximately $8.4 billion in 2026 and growing at over twenty percent annually toward $22 billion by 2031, spans the treatment monitoring segment whose revenue is anchored by the established Guardant360, FoundationOne Liquid CDx, and Tempus xF assays deployed in oncology centres, and the multi-cancer early detection segment whose commercial trajectory is being shaped by the GRAIL Galleri test whose NHS England pilot and US commercial launch represent the first large-scale real-world deployment of a multi-cancer early detection product in a healthcare system context. The two segments differ not only in their patient populations and clinical applications but in their reimbursement dynamics, their sales channel requirements, and the competitive structure of the markets they create, making the liquid biopsy market's commercial evolution a story of two distinct products that share a biological principle but serve different payers, different buyers, and different healthcare system functions.
GRAIL and the Multi-Cancer Early Detection Commercial Launch
GRAIL, the US liquid biopsy company whose Galleri multi-cancer early detection test simultaneously screens for the DNA methylation signal of more than fifty cancer types from a single blood draw, has navigated the most commercially complex launch in the history of liquid biopsy diagnostics through the combination of its NHS England Galleri trial, whose 140,000-participant randomised controlled trial is the largest cancer screening study conducted in the United Kingdom in recent history, its US direct-to-consumer and employer health benefit commercial launch at approximately $950 per test, and the regulatory pathway whose FDA Breakthrough Device Designation and Pre-Submission engagement have defined the evidence requirements for the FDA approval that would unlock Medicare reimbursement and the mass-market health system adoption that self-pay and employer benefit deployment alone cannot achieve at the scale that makes MCED screening commercially transformative. Its acquisition by Illumina, the DNA sequencing company, in 2021 and the subsequent forced divestiture ordered by the European Commission and US FTC, whose antitrust concerns about Illumina owning both the sequencing platform and the liquid biopsy company whose assay depends on that platform, created the regulatory and corporate complexity that has overlapped with GRAIL's clinical and commercial development in a way that no liquid biopsy company had previously encountered. Guardant Health, whose Guardant360 treatment monitoring assay is the market-leading companion diagnostic for oncology treatment selection and whose Shield colorectal cancer early detection test received FDA approval in July 2024, represents the alternative commercial trajectory in which the well-established oncology treatment monitoring revenue base funds the expansion into early detection through a single-cancer test whose FDA approval provides the regulatory foundation for the broader MCED pipeline.
Exact Sciences, the US molecular diagnostics company whose Cologuard stool DNA test for colorectal cancer screening is the most commercially successful cancer screening test launched in the past decade, is developing its liquid biopsy early detection programme as the blood-based complement to Cologuard whose non-invasive sample collection advantage over colonoscopy has driven its commercial adoption but whose stool sample requirement creates the patient experience friction that a blood-based test eliminates. Its Oncotype DX breast and prostate cancer genomic assays, which predict whether early-stage cancer patients require chemotherapy based on their tumour's genetic profile, represent the treatment guidance application of liquid biopsy whose established Medicare reimbursement and its integration into oncology treatment guidelines provides the commercial model that MCED tests are working toward through their own guideline inclusion and reimbursement coverage processes. Foundation Medicine, the Roche subsidiary whose FoundationOne Liquid CDx comprehensive genomic profiling assay is FDA-approved as a companion diagnostic for multiple targeted therapies in lung, breast, colorectal, and ovarian cancer, provides the treatment monitoring revenue anchor whose established oncology centre relationships and its Roche diagnostic infrastructure create the commercial distribution that an independent liquid biopsy company must build from scratch.
The Reimbursement Barrier and the Diagnostic Lab Disruption
The structural challenge that liquid biopsy multi-cancer early detection must overcome before its clinical utility translates into commercial scale is the reimbursement coverage decision whose complexity reflects both the evidence standard that CMS applies to population screening tests and the health economics argument that early cancer detection's reduction in late-stage treatment cost justifies the screening test's per-patient cost at the population level. The diagnostic laboratory business model disruption that liquid biopsy creates operates through two mechanisms: the shift of cancer diagnostic revenue from the tissue pathology laboratory whose surgical biopsy processing and immunohistochemistry staining generates the majority of its oncology revenue toward the molecular diagnostics laboratory whose liquid biopsy NGS sequencing capabilities create the new revenue source, and the potential shift of cancer screening volume from the gastroenterologist's colonoscopy suite and the radiologist's CT scan toward the primary care blood draw whose simplicity and accessibility create the screening participation rates that invasive and imaging-based screening programmes cannot match.
Top 10 Companies in Liquid Biopsy and Multi-Cancer Early Detection Globally
- GRAIL (Galleri): US multi-cancer early detection company with 140,000-participant NHS England trial and US commercial launch at $950 per test; its methylation-based MCED technology and its NHS pilot scale create the liquid biopsy company whose multi-cancer detection breadth and real-world deployment evidence define the clinical and commercial benchmark for population cancer screening.
- Guardant Health: US liquid biopsy company with Guardant360 treatment monitoring and Shield FDA-approved colorectal early detection; its oncology treatment monitoring revenue base and its Shield CRC approval create the liquid biopsy company whose established oncology channel and its FDA approval pathway provide the commercial infrastructure for MCED expansion.
- Exact Sciences: US molecular diagnostics company with Cologuard colorectal screening and Oncotype DX treatment guidance and liquid biopsy early detection development; its Cologuard commercial distribution through primary care and its Oncotype Medicare reimbursement create the diagnostics company whose non-invasive cancer testing heritage positions it most naturally for the blood-based MCED market.
- Foundation Medicine (Roche): US comprehensive genomic profiling company with FoundationOne Liquid CDx FDA-approved companion diagnostic; its Roche infrastructure and its companion diagnostic approvals across multiple cancer types create the liquid biopsy treatment monitoring company whose regulatory approvals and oncology centre penetration are the most commercially established of any liquid biopsy assay globally.
- Illumina: US DNA sequencing company whose next-generation sequencing technology is the platform underlying most liquid biopsy assays; its NovaSeq and NextSeq sequencing infrastructure and its sequencing reagent supply create the enabling technology company whose sequencing economics determine the per-test cost floor below which liquid biopsy assay pricing cannot fall.
- Biodesix: US lung cancer diagnostic company with Nodify Lung blood-based pulmonary nodule risk assessment; its lung cancer early detection focus and its blood protein biomarker approach create the liquid biopsy company whose single-cancer focus delivers the clinical specificity that multi-cancer screening tests sacrifice for breadth.
- Sysmex: Japanese diagnostic equipment company with circulating tumour DNA liquid biopsy assays for the Japanese clinical market; its haematology analyser installed base and its Japanese oncology market relationships create the liquid biopsy company whose Asian market penetration serves the Japanese national cancer screening programme whose scale creates one of the world's largest addressable liquid biopsy markets outside the US and UK.
- ANGLE: UK liquid biopsy company with Parsortix circulating tumour cell harvesting system; its CTC isolation technology and its FDA clearance for metastatic breast cancer CTC harvesting create the liquid biopsy company whose circulating tumour cell approach complements the ctDNA methodology of the major US liquid biopsy companies with a different biological signal that provides treatment monitoring information that cell-free DNA cannot capture.
- Singlera Genomics: Chinese liquid biopsy company with PanSeer multi-cancer early detection for the Chinese market; its Chinese regulatory pathway and its methylation-based multi-cancer detection create the Asian market liquid biopsy company whose Chinese population screening ambitions mirror GRAIL's Western market strategy in the world's most populous cancer screening addressable market.
- Tempus AI: US AI-enabled precision medicine company with xF liquid biopsy assay and clinical data platform; its AI analysis of ctDNA and clinical data and its oncology centre data partnerships create the liquid biopsy company whose differentiation from pure-play diagnostics companies is the AI-driven treatment insight layer that converts genomic sequencing data into actionable clinical decision support beyond the variant report.